Abnormal Long Non-Coding RNAs Expression Patterns Have the Potential Ability for Predicting Survival and Treatment Response in Breast Cancer

Imagem de Miniatura
Arquivos
art_PAVANELLI_Abnormal_Long_NonCoding_RNAs_Expression_Patterns_Have_the_2021.PDF (2.69 MB)
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Autores
Citação
GENES, v.12, n.7, article ID 996, 12p, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Abnormal long non-coding RNAs (lncRNAs) expression has been documented to have oncogene or tumor suppressor functions in the development and progression of cancer, emerging as promising independent biomarkers for molecular cancer stratification and patients' prognosis. Examining the relationship between lncRNAs and the survival rates in malignancies creates new scenarios for precision medicine and targeted therapy. Breast cancer (BRCA) is a heterogeneous malignancy. Despite advances in its molecular classification, there are still gaps to explain in its multifaceted presentations and a substantial lack of biomarkers that can better predict patients' prognosis in response to different therapeutic strategies. Here, we performed a re-analysis of gene expression data generated using cDNA microarrays in a previous study of our group, aiming to identify differentially expressed lncRNAs (DELncRNAs) with a potential predictive value for response to treatment with taxanes in breast cancer patients. Results revealed 157 DELncRNAs (90 up- and 67 down-regulated). We validated these new biomarkers as having prognostic and predictive value for breast cancer using in silico analysis in public databases. Data from TCGA showed that compared to normal tissue, MIAT was up-regulated, while KCNQ1OT1, LOC100270804, and FLJ10038 were down-regulated in breast tumor tissues. KCNQ1OT1, LOC100270804, and FLJ10038 median levels were found to be significantly higher in the luminal subtype. The ROC plotter platform results showed that reduced expression of these three DElncRNAs was associated with breast cancer patients who did not respond to taxane treatment. Kaplan-Meier survival analysis revealed that a lower expression of the selected lncRNAs was significantly associated with worse relapse-free survival (RFS) in breast cancer patients. Further validation of the expression of these DELncRNAs might be helpful to better tailor breast cancer prognosis and treatment.
Palavras-chave
breast cancer, lncRNAs, prognosis, docetaxel, biomarkers
URI
https://observatorio.fm.usp.br/handle/OPI/41594
Referências
  1. Alipoor FJ, 2018, J CELL BIOCHEM, V119, P6470, DOI 10.1002/jcb.26678
  2. Allemani C, 2018, LANCET, V391, P1023, DOI 10.1016/S0140-6736(17)33326-3
  3. Almnaseer ZA, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180704
  4. Barsyte-Lovejoy D, 2006, CANCER RES, V66, P5330, DOI 10.1158/0008-5472.CAN-06-0037
  5. Bartella V, 2012, BREAST CANCER RES TR, V134, P569, DOI 10.1007/s10549-012-2090-9
  6. Bhan A, 2017, CANCER RES, V77, P3965, DOI 10.1158/0008-5472.CAN-16-2634
  7. Bond HM, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00255
  8. Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
  9. Cech TR, 2014, CELL, V157, P77, DOI 10.1016/j.cell.2014.03.008
  10. Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
  11. Chi YY, 2014, CANCER CELL INT, V14, DOI 10.1186/s12935-014-0123-7
  12. Chi YJ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091015
  13. Corra F, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00327
  14. Garcia SAD, 2017, INT J MOL MED, V39, P809, DOI 10.3892/ijmm.2017.2900
  15. Dong ZW, 2019, J CELL PHYSIOL, V234, P11304, DOI 10.1002/jcp.27788
  16. Fekete JT, 2019, INT J CANCER, V145, P3140, DOI 10.1002/ijc.32369
  17. Feng W., 2018, CELL PHYSIOL BIOCHEM, V49, P432, DOI [10.1159/000492978, DOI 10.1159/000492978]
  18. Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
  19. Goldman MJ, 2020, NAT BIOTECHNOL, V38, P675, DOI 10.1038/s41587-020-0546-8
  20. Green KA, 2007, NAT REV CANCER, V7, P713, DOI 10.1038/nrc2211
  21. Hajjari M, 2015, CANCER BIOL MED, V12, P1, DOI 10.7497/j.issn.2095-3941.2015.0006
  22. Huang J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.541
  23. Ingle JN, 2013, CANCER DISCOV, V3, P812, DOI 10.1158/2159-8290.CD-13-0038
  24. Ishii N, 2006, J HUM GENET, V51, P1087, DOI 10.1007/s10038-006-0070-9
  25. Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011
  26. Li DZ, 2020, CELL SIGNAL, V73, DOI 10.1016/j.cellsig.2020.109697
  27. Li YH, 2018, BIOCHEM BIOPH RES CO, V503, P45, DOI 10.1016/j.bbrc.2018.05.146
  28. Luan T, 2017, ONCOTARGET, V8, P76153, DOI 10.18632/oncotarget.19190
  29. Milani A, 2014, WORLD J CLIN ONCOL, V5, P990, DOI 10.5306/wjco.v5.i5.990
  30. Mohammad F, 2008, MOL CELL BIOL, V28, P3713, DOI 10.1128/MCB.02263-07
  31. Moore JE, 2020, NATURE, V583, P699, DOI 10.1038/s41586-020-2493-4
  32. Nagy A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27521-y
  33. Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
  34. Perry RB, 2016, DEVELOPMENT, V143, P3882, DOI 10.1242/dev.140962
  35. Pickard MR, 2016, ONCOTARGET, V7, P10104, DOI 10.18632/oncotarget.7173
  36. Richard John Lalith Charles, 2018, Oncotarget, V9, P20179, DOI 10.18632/oncotarget.24591
  37. Rodriguez BAT, 2011, CARCINOGENESIS, V32, P812, DOI 10.1093/carcin/bgr017
  38. Romano G, 2017, CARCINOGENESIS, V38, P485, DOI 10.1093/carcin/bgx026
  39. Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5
  40. Shen B, 2020, CANCER GENE THER, DOI 10.1038/s41417-020-00254-9
  41. Si XX, 2016, ONCOTARGET, V7, P81452, DOI 10.18632/oncotarget.13263
  42. Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
  43. Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
  44. Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247
  45. Wang G, 2019, BREAST CANCER RES TR, V175, P567, DOI 10.1007/s10549-019-05194-z
  46. Wang J, 2017, ONCOTARGET, V8, P5508, DOI 10.18632/oncotarget.12537
  47. Xie JJ, 2019, ONCOL LETT, V18, P838, DOI 10.3892/ol.2019.10357
  48. Xu SP, 2016, ONCOTARGET, V7, P20704, DOI 10.18632/oncotarget.8007
  49. Zhou GY, 2019, NUCLEIC ACIDS RES, V47, pW234, DOI 10.1093/nar/gkz240
  50. Zhou SY, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180772

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - LIM/03
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - ODS/03